Phase II Study of Lenalidomide in Combination With Nivolumab In Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Lenalidomide (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 May 2019 Status changed from recruiting to discontinued.
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.
- 26 Feb 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.